Melanoma: Epidemiology, Risk Factors, Pathogenesis, Diagnosis and Classification
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Orbital Involvement with Desmoplastic Melanoma*
Br J Ophthalmol: first published as 10.1136/bjo.71.4.279 on 1 April 1987. Downloaded from British Journal of Ophthalmology, 1987, 71, 279-284 Orbital involvement with desmoplastic melanoma* JERRY A SHIELDS,'4 DAVID ELDER,2 VIOLETTA ARBIZO,4 THOMAS HEDGES,' AND JAMES J AUGSBURGER' From the 'Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, the 'Pigmented Lesion Group, Department of Dermatology and of Pathology and Laboratory Medicine, University of Pennsylvawa, the 'Department of Ophthalmology, Pennsylvania Hospital, and the 4Pathology Department, Wills Eye Hospital, USA. SUMMARY A 79-year-old woman developed an orbital mass five and a half years after excision of a cutaneous melanoma from the side of the nose. The initial orbital biopsy was interpreted histopathologically as a malignant fibrous histiocytoma, but special stains and electron microscopy showed it to be a desmoplastic malignant melanoma which had apparently spread to the orbit from the prioriskin lesion by neurotropic mechanisms. The occurrence of a desmoplastic neurotropic melanoma in the orbit has not been previously recognised. The problems in the clinical and pathological diagnosis of this rare type of melanoma are discussed. Orbital involvement with malignant melanoma most August 1984 she had excision of scar tissue around often occurs secondary to extrascleral extension the left eye and biopsy of a 'cyst' in the left upper of posteribr uveal melanoma.' Primary orbital eyelid, which was diagnosed at another hospital as a melanoma and metastatic cutaneous melanoma malignant fibrous histiocytoma. http://bjo.bmj.com/ to the orbit are extremely rare.2 Desmoplastic A general physical examination gave essentially melanoma is a rare form of cutaneous melanoma normal results, and complete examination of the which can extend from a superficial location into the right eye revealed no abnormalities. -
Meta Analyses – Pros and Cons
Meta analyses – pros and cons Emily S Sena, PhD Centre for Clinical Brain Sciences, University of Edinburgh @camarades_ CAMARADES: Bringing evidence to translational medicine CAMARADES • Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies • Look systematically across the modelling of a range of conditions • Data Repository – 30 Diseases – 40 Projects – 25,000 studies – from over 400,000 animals CAMARADES: Bringing evidence to translational medicine Why do we do meta-analysis of animal studies? • Animal models are generally performed to inform human health but when should you be convinced to move to the next step? • Systematic reviews & meta-analyses: – assess the quality and range of evidence – identify gaps in the field – quantify relative utility of outcome measures – inform power/sample size calculations – assess for publication bias – try to explain discrepancies between preclinical and clinical trial results – inform clinical trial design CAMARADES: Bringing evidence to translational medicine Systematic review and meta-analysis • Pros – What have we learnt about…….. • Translation? • Quality? • The 3Rs? • Cons – What are the limitations? • As good as the data that goes in? • Rapidly outdated • The Impact CAMARADES: Bringing evidence to translational medicine Systematic review and meta-analysis • Pros – What have we learnt about…….. • Translation? • Quality? • The 3Rs? • Cons – What are the limitations? • As good as the data that goes in? • Rapidly outdated • The Impact CAMARADES: Bringing evidence -
Melanocytic Lesions of the Face—SW Mccarthy & RA Scolyer 3 Review Article
Melanocytic Lesions of the Face—SW McCarthy & RA Scolyer 3 Review Article Melanocytic Lesions of the Face: Diagnostic Pitfalls* 1,2 1,2 SW McCarthy, MBBS, FRCPA, RA Scolyer, MBBS, FRCPA Abstract The pathologist often has a difficult task in evaluating melanocytic lesions. For lesions involving the face the consequences of misdiagnosis are compounded for both cosmetic and therapeutic reasons. In this article, the pathological features of common and uncommon benign and malignant melanocytic lesions are reviewed and pitfalls in their diagnosis are highlighted. Benign lesions resembling melanomas include regenerating naevus, “irritated” naevus, com- bined naevus, “ancient naevus”, Spitz naevus, dysplastic naevus, halo naevus, variants of blue naevi, balloon and clear cell naevi, neurotised naevus and desmoplastic naevus. Melanomas that can easily be missed on presentation include desmoplastic, naevoid, regressed, myxoid and metastatic types as well as so-called malignant blue naevi. Pathological clues to benign lesions include good symmetry, V-shaped silhouette, absent epidermal invasion, uniform cellularity, deep maturation, absent or rare dermal mitoses and clustered Kamino bodies. Features more commonly present in melanomas include asymmetry, peripheral epidermal invasion, heavy or “dusty” pigmentation, deep and abnormal dermal mitoses, HMB45 positivity in deep dermal melanocytes, vascular invasion, neurotropism and satellites. Familiarity with the spectrum of melanocytic lesions and knowledge of the important distinguishing features should -
Adaptive Enrichment Designs in Clinical Trials
Annual Review of Statistics and Its Application Adaptive Enrichment Designs in Clinical Trials Peter F. Thall Department of Biostatistics, M.D. Anderson Cancer Center, University of Texas, Houston, Texas 77030, USA; email: [email protected] Annu. Rev. Stat. Appl. 2021. 8:393–411 Keywords The Annual Review of Statistics and Its Application is adaptive signature design, Bayesian design, biomarker, clinical trial, group online at statistics.annualreviews.org sequential design, precision medicine, subset selection, targeted therapy, https://doi.org/10.1146/annurev-statistics-040720- variable selection 032818 Copyright © 2021 by Annual Reviews. Abstract All rights reserved Adaptive enrichment designs for clinical trials may include rules that use in- terim data to identify treatment-sensitive patient subgroups, select or com- pare treatments, or change entry criteria. A common setting is a trial to Annu. Rev. Stat. Appl. 2021.8:393-411. Downloaded from www.annualreviews.org compare a new biologically targeted agent to standard therapy. An enrich- ment design’s structure depends on its goals, how it accounts for patient heterogeneity and treatment effects, and practical constraints. This article Access provided by University of Texas - M.D. Anderson Cancer Center on 03/10/21. For personal use only. first covers basic concepts, including treatment-biomarker interaction, pre- cision medicine, selection bias, and sequentially adaptive decision making, and briefly describes some different types of enrichment. Numerical illus- trations are provided for qualitatively different cases involving treatment- biomarker interactions. Reviews are given of adaptive signature designs; a Bayesian design that uses a random partition to identify treatment-sensitive biomarker subgroups and assign treatments; and designs that enrich superior treatment sample sizes overall or within subgroups, make subgroup-specific decisions, or include outcome-adaptive randomization. -
Types of Melanoma
Types of Melanoma Melanoma is classified into different types. Classification is based on their colour, shape, location, and how they grow. Superficial spreading melanoma Superficial spreading melanoma usually looks like a dark brown or black stain spreading from an existing or a new mole. This type of melanoma is more commonly seen in areas of skin that have been exposed to UV light, especially areas of previous sunburn. It is the most common type, making up 70% of melanomas. Superficial spreading melanoma tends to follow the ABCDE rules. In most situations, the early changes are purely visual ones and it is the later stages that may result in symptoms (itching or bleeding). In addition to the skin surfaces, melanoma can also present in mucosal surfaces such as the mouth or genital area. Nodular melanoma Nodular melanoma is a firm, domed bump. It grows quickly down through the epidermis into the dermis. Once there, it can metastasize, or spread to other parts of the body. Nodular melanoma makes up about 10% of all melanomas. Nodular melanoma is typically dark brown or black, may crust or ulcerate. As in all sub-types of melanoma, nodular melanoma can present without any colour or a pink, red or skin toned colour (amelanotic), especially in people with very fair complexions. Lentigo maligna melanoma Lentigo maligna melanoma looks like a dark stain which may have looked initially like a large or irregular freckle. It has an uneven border and irregular colour. It is usually seen on the face or arms of middle aged and older people. -
Use of in Vivo and in Vitro Models to Guide Dose Selection for Neonatal Infections
Use of In Vivo and In Vitro Models to Guide Dose Selection for Neonatal Infections Professor William Hope Antimicrobial Pharmacodynamics & Therapeutics University of Liverpool September 2016 Disclosures • William Hope has received research funding from Pfizer, Gilead, Astellas, AiCuris, Amplyx, Spero Therapeutics and F2G, and acted as a consultant and/or given talks for Pfizer, Basilea, Astellas, F2G, Nordic Pharma, Medicines Company, Amplyx, Mayne Pharma, Spero Therapeutics, Auspherix, Cardeas and Pulmocide. First of all BIOMARKER OUTCOME OF CLINICAL DOSE INTEREST/IMPORTANCE •Decline in Log10CFU/mL •Linked to an outcome of clinical interest •Survival 7 6 5 4 CFU/g) CNS 10 3 Effect (log 2 1 0 0.01 0.1 1 10 100 1000 Total doseDose 5FC (mg/kg) PHARMACOKINETICS PHARMACODYNAMICS Concept of Expensive Failure COST Derisking White Powder Preclinical Program Clinical Program Concept from Trevor Mundell & Gates Foundation And this… Normal Therapeutics Drug A, Dose A1 versus Drug B, Dose B1 Pharmacodynamics is the Bedrock of ALL Therapeutics…it sits here without being seen One of the reasons simple scaling does not work is the fact pharmacodynamics are different Which means the conditions that govern exposure response relationships in neonates need to be carefully considered …Ignore these at your peril Summary of Preclinical Pharmacodynamic Studies for Neonates** • Hope el al JID 2008 – Micafungin for neonates – Primary question of HCME – Rabbit model with hematogenous dissemination • Warn et al AAC 2010 – Anidulafungin for neonates – Primary question -
Role and Limitations of Epidemiology in Establishing a Causal Association Eduardo L
Seminars in Cancer Biology 14 (2004) 413–426 Role and limitations of epidemiology in establishing a causal association Eduardo L. Franco a,∗, Pelayo Correa b, Regina M. Santella c, Xifeng Wu d, Steven N. Goodman e, Gloria M. Petersen f a Departments of Epidemiology and Oncology, McGill University, 546 Pine Avenue West, Montreal, QC, Canada H2W1S6 b Department of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA, USA c Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA d Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA e Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA f Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA Abstract Cancer risk assessment is one of the most visible and controversial endeavors of epidemiology. Epidemiologic approaches are among the most influential of all disciplines that inform policy decisions to reduce cancer risk. The adoption of epidemiologic reasoning to define causal criteria beyond the realm of mechanistic concepts of cause-effect relationships in disease etiology has placed greater reliance on controlled observations of cancer risk as a function of putative exposures in populations. The advent of molecular epidemiology further expanded the field to allow more accurate exposure assessment, improved understanding of intermediate endpoints, and enhanced risk prediction by incorporating the knowledge on genetic susceptibility. We examine herein the role and limitations of epidemiology as a discipline concerned with the identification of carcinogens in the physical, chemical, and biological environment. We reviewed two examples of the application of epidemiologic approaches to aid in the discovery of the causative factors of two very important malignant diseases worldwide, stomach and cervical cancers. -
Melanomas Are Comprised of Multiple Biologically Distinct Categories
Melanomas are comprised of multiple biologically distinct categories, which differ in cell of origin, age of onset, clinical and histologic presentation, pattern of metastasis, ethnic distribution, causative role of UV radiation, predisposing germ line alterations, mutational processes, and patterns of somatic mutations. Neoplasms are initiated by gain of function mutations in one of several primary oncogenes, typically leading to benign melanocytic nevi with characteristic histologic features. The progression of nevi is restrained by multiple tumor suppressive mechanisms. Secondary genetic alterations override these barriers and promote intermediate or overtly malignant tumors along distinct progression trajectories. The current knowledge about pathogenesis, clinical, histological and genetic features of primary melanocytic neoplasms is reviewed and integrated into a taxonomic framework. THE MOLECULAR PATHOLOGY OF MELANOMA: AN INTEGRATED TAXONOMY OF MELANOCYTIC NEOPLASIA Boris C. Bastian Corresponding Author: Boris C. Bastian, M.D. Ph.D. Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology Departments of Dermatology and Pathology University of California, San Francisco UCSF Cardiovascular Research Institute 555 Mission Bay Blvd South Box 3118, Room 252K San Francisco, CA 94158-9001 [email protected] Key words: Genetics Pathogenesis Classification Mutation Nevi Table of Contents Molecular pathogenesis of melanocytic neoplasia .................................................... 1 Classification of melanocytic neoplasms -
(GIVIMP) for the Development and Implementation of in Vitro Methods for 829 Regulatory Use in Human Safety Assessment
1 2 Draft GUIDANCE DOCUMENT ON GOOD IN VITRO METHOD PRACTICES (GIVIMP) 3 FOR THE DEVELOPMENT AND IMPLEMENTATION OF IN VITRO METHODS FOR 4 REGULATORY USE IN HUMAN SAFETY ASSESSMENT 5 6 FOREWORD 7 8 A guidance document on Good In Vitro Method Practices (GIVIMP) for the development and 9 implementation of in vitro methods for regulatory use in human safety assessment was 10 identified as a high priority requirement. The aim is to reduce the uncertainties in cell and 11 tissue-based in vitro method derived predictions by applying all necessary good scientific, 12 technical and quality practices from in vitro method development to in vitro method 13 implementation for regulatory use. 14 The draft guidance is coordinated by the European validation body EURL ECVAM and has 15 been accepted on the work plan of the OECD test guideline programme since April 2015 as a 16 joint activity between the Working Group on Good Laboratory Practice (GLP) and the 17 Working Group of the National Coordinators of the Test Guidelines Programme (WNT). 18 The draft document prepared by the principal co-authors has been sent in September 2016 to 19 all 37 members of the European Union Network of Laboratories for the Validation of 20 Alternative Methods (EU-NETVAL1) and has been subsequently discussed at the EU- 21 NETVAL meeting on the 10th of October 2016. 22 By November/December 2016 the comments of the OECD Working Group on GLP and 23 nominated experts of the OECD WNT will be forwarded to EURL ECVAM who will 24 incorporate these and prepare an updated version. -
Medicolegal Aspects of Neoplastic Dermatology
Modern Pathology (2006) 19, S148–S154 & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Medicolegal aspects of neoplastic dermatology A Neil Crowson Departments of Dermatology, Pathology, and Surgery, University of Oklahoma and Regional Medical Laboratory, St John Medical Center, Tulsa, OK, USA Medical malpractice litigation is rising at an explosive rate in the US and, to a lesser extent, in Canada. The impact of medical malpractice litigation on health care costs and the cost of insurance is dramatic. Certain specialist categories are becoming uninsurable in some parts of the US, while in others, clinicians are retiring early, restricting or changing practice or changing states of residence in consequence of medical malpractice claims and of the cost and availability of insurance. This, in turn, has had the real effect of denying care to patients in some communities in the US. Some 13% of all medical malpractice claims relate to one area of neoplastic dermatopathology, specifically, melanocytic neoplasia. Certain steps can be taken by pathology laboratories to reduce, but never completely eliminate, the risk of medical malpractice claims. In this review, attention is paid to the source of medical malpractice claims and an abbreviated approach to specific strategies for risk management is presented. Modern Pathology (2006) 19, S148–S154. doi:10.1038/modpathol.3800518 Keywords: malpractice; dermatopathology; risk management; case review Medical malpractice claims and settlements have pathologist who was formerly deemed to be in the skyrocketed across the US. Some malpractice in- background of patient care. Those clinicians who surers are no longer covering physicians,1 and the practice cosmetic dermatology are at even greater issue of uninsured physicians leaving medical risk. -
Genomic Copy Number Analysis of a Spectrum of Blue Nevi Identifies
Modern Pathology (2016) 29, 227–239 © 2016 USCAP, Inc All rights reserved 0893-3952/16 $32.00 227 Genomic copy number analysis of a spectrum of blue nevi identifies recurrent aberrations of entire chromosomal arms in melanoma ex blue nevus May P Chan1,2, Aleodor A Andea1,2, Paul W Harms1,2, Alison B Durham2, Rajiv M Patel1,2, Min Wang1, Patrick Robichaud2, Gary J Fisher2, Timothy M Johnson2 and Douglas R Fullen1,2 1Department of Pathology, University of Michigan, Ann Arbor, MI, USA and 2Department of Dermatology, University of Michigan, Ann Arbor, MI, USA Blue nevi may display significant atypia or undergo malignant transformation. Morphologic diagnosis of this spectrum of lesions is notoriously difficult, and molecular tools are increasingly used to improve diagnostic accuracy. We studied copy number aberrations in a cohort of cellular blue nevi, atypical cellular blue nevi, and melanomas ex blue nevi using Affymetrix’s OncoScan platform. Cases with sufficient DNA were analyzed for GNAQ, GNA11, and HRAS mutations. Copy number aberrations were detected in 0 of 5 (0%) cellular blue nevi, 3 of 12 (25%) atypical cellular blue nevi, and 6 of 9 (67%) melanomas ex blue nevi. None of the atypical cellular blue nevi displayed more than one aberration, whereas complex aberrations involving four or more regions were seen exclusively in melanomas ex blue nevi. Gains and losses of entire chromosomal arms were identified in four of five melanomas ex blue nevi with copy number aberrations. In particular, gains of 1q, 4p, 6p, and 8q, and losses of 1p and 4q were each found in at least two melanomas. -
Dermatopathology ▲
408 DERMATOPATHOLOGY ▲ Desmoplastic melanoma associated with an intraepidermal lentiginous lesion: case report and literature review* Melanoma desmoplásico associado a lesão lentiginosa intraepidérmica, com evolução de 10 anos: relato de caso e revisão bibliográfica Cesar de Souza Bastos Junior1 Juan Manuel Piñeiro-Maceira2 Fernando Manuel Belles de Moraes3 DOI: http://dx.doi.org/10.1590/abd1806-4841.20131817 Abstract: Desmoplastic melanoma tends to present as firm, amelanotic papules. Microscopically, it reveals a pro- liferation of fusiform cells in the dermis and variable collagen deposition, as well as intraepidermal melanocytic proliferation of lentiginous type in most cases. Biopsy in a 61-year-old white male patient, who had received a diagnosis of lentigo maligna on his face 10 years before, revealed a proliferation of dermal pigmented spindle cells and collagen deposition, reaching the deep reticular dermis, with a lentiginous component. Immunohistochemistry with S-100, Melan-A and WT1 showed positivity, but it was weak with HMB45. Desmoplastic melanoma associated with lentigo maligna was diagnosed. Several authors discuss whether desmoplastic melanoma represents a progression from the lentiginous component or arises “de novo”. Desmoplastic melanoma represents a minority of cases of primary cutaneous melanoma (less than 4%). Identification of lentigo maligna indicates that desmoplastic melanoma should be carefully investigated. Keywords: Melanoma; Nevus, epithelioid and spindle cell; S100 Proteins; WT1 Protein Resumo: Os melanomas desmoplásicos apresentam-se como pápulas amelanóticas firmes; à microscopia exibem proliferação de células fusiformes na derme e variável deposição de colágeno, além de proliferação melanocítica lentiginosa, intraepidérmica, na maioria dos casos. Realizada biópsia de pele de paciente masculino, 61 anos, branco, com diagnóstico de lentigo maligno na face, há 10 anos.